Additionally, we validate decitabine-upregulated CSPG4 as bona fide target antigen for CAR-T cells by demonstrating antigen-specific cytotoxicity as well as antigen-specific cytokine secretion of CSPG4-specific CAR-T cells in response to decitabine-treated SKOV-3 ovarian carcinoma cells. This evidence concerns the gene CSPG4 and ovarian carcinoma.